AstraZeneca PLC (AZN)vsBioLife Solutions Inc (BLFS)
AZN
AstraZeneca PLC
$168.90
-0.23%
HEALTHCARE · Cap: $261.94B
BLFS
BioLife Solutions Inc
$29.15
-3.67%
HEALTHCARE · Cap: $1.36B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 59352% more annual revenue ($60.44B vs $101.66M). AZN leads profitability with a 17.2% profit margin vs -2.9%. AZN appears more attractively valued with a PEG of 1.33. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
BLFS
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.0%
Fair Value
$194.22
Current Price
$168.90
$25.32 discount
Margin of Safety
-9.0%
Fair Value
$20.42
Current Price
$29.15
$8.73 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 24.7% year-over-year
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Smaller company, higher risk/reward
Operating margin of 0.1%
Expensive relative to growth rate
ROE of -2.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : BLFS
The strongest argument for BLFS centers on Debt/Equity, Altman Z-Score, Revenue Growth. Revenue growth of 24.7% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : BLFS
The primary concerns for BLFS are Market Cap, Operating Margin, PEG Ratio.
Key Dynamics to Monitor
AZN profiles as a mature stock while BLFS is a growth play — different risk/reward profiles.
BLFS carries more volatility with a beta of 1.94 — expect wider price swings.
BLFS is growing revenue faster at 24.7% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 30/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
BioLife Solutions Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the gene and cell therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company is headquartered in Bothell, Washington.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?